(Q33382991)

26 July 2017

1 reference

title

Posaconazole: a new oral antifungal agent with an expanded spectrum of activity (English)

1 reference

26 July 2017

Michele I Morris

1

1 reference

26 July 2017

publication date

1 February 2009

1 reference

American Journal of Health-System Pharmacy

26 July 2017

published in

1 reference

26 July 2017

volume

66

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

225-236

1 reference

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Role of new antifungal agents in prophylaxis of mycoses in high risk patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole as salvage therapy for zygomycosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Activity of posaconazole in the treatment of central nervous system fungal infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole: a broad-spectrum triazole antifungal

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

The changing face of invasive fungal infections in hematopoietic cell transplant recipients.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Zygomycosis (mucormycosis): emerging clinical importance and new treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Zygomycosis: the re-emerging fungal infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Changing face of health-care associated fungal infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Management of systemic fungal infections: alternatives to itraconazole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole (Noxafil): a new triazole antifungal agent.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole plasma concentrations in juvenile patients with invasive fungal infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Disposition of posaconazole following single-dose oral administration in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Efficacy of posaconazole in a murine model of central nervous system aspergillosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Pharmacokinetics and pharmacodynamics of antifungals

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

In vitro antifungal susceptibilities of Trichosporon species.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Activity of posaconazole in treatment of experimental disseminated zygomycosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Azole cross-resistance in Aspergillus fumigatus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

In vitro activity of posaconazole against clinical isolates of dermatophytes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

In vitro antifungal activity of posaconazole against various pathogenic fungi

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole: clinical pharmacology and potential for management of fungal infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Clinical evaluation of the Sensititre YeastOne plate for testing susceptibility of filamentous fungi to posaconazole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole susceptibility testing against Candida species: comparison of broth microdilution and E-test methods

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: comparison with CLSI broth microdilution method

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Role of antifungal susceptibility testing in patient management

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Antifungal combination therapy: clinical potential

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Combinations of antifungal agents in therapy--what value are they?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

SCH56592 treatment of murine invasive aspergillosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Zygomycosis in neutropenic patients with past Aspergillus infection: a role for posaconazole?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Refractory coccidioidomycosis treated with posaconazole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Treatment of histoplasmosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Salvage treatment of histoplasmosis with posaconazole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Chronic refractory phaeohyphomycosis: successful treatment with posaconazole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Antifungal susceptibilities of the species of the Pseudallescheria boydii complex

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

Antifungal prophylaxis for invasive mycoses in high risk patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070532

31 March 2020

Identifiers

DOI

10.2146/AJHP070532

1 reference

26 July 2017

1 reference